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Background: In the United States, chronic obstructive pulmonary disease (COPD) diagnosis is
often a lengthy process, and consequently results in delays in treatment in early stages.
Disease progression and complication may result in increased levels of healthcare service
use. To understand the economic burden of COPD prior to diagnosis in the U.S., trends in utili-
zation and costs during the period before initial COPD diagnosis were compared with matched
controls.
Methods: A retrospective case-control study was conducted using medical and pharmacy
claims data from a large managed care health plan representing a base population of over
30 million covered lives in the U.S. COPD patients with at least 12 months of continuous enroll-
ment and aged 40 years or older were identified (nZ 28,968) and matched to up to three
random controls (nZ 81,322) by age, gender, region of plans and index date. Multivariate
regression models were used to estimate average incremental service use and cost between
COPD patients and controls. Moreover, trends in utilization and costs for the COPD patients
were examined over 36 months before diagnosis.
Results: COPD patients used 1.5e1.6 times more inpatient/emergency department (IP/ED)
services and office visits compared to control patients. The average incremental annual costs
for IP/ED services, office visits, and medical and pharmacy services were estimated at $550,
$238, $1438 and $401, respectively, after adjusting for age, gender, region and comorbid
conditions. The 36-month trend analysis showed that COPD patients’ healthcare utilization
and costs increased gradually over time, often with a marked increase in the month before
COPD diagnosis.5 216 7695; fax: þ1 505 348 8541.
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prior to diagnosis. More timely diagnosis and subsequent treatment may avoid costly health-
care utilization and unnecessary mortality and morbidity post-diagnosis.
ª 2008 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disorder (COPD) is a treat-
able and preventable lung disease, with a pulmonary
component characterized by airflow limitation that is not
fully reversible.1 Its burden upon patients, providers, and
society is enormous and growing annually. COPD affects
more than 20 million Americans2 and is now the fourth most
common cause of death (exceeded only by heart disease,
cancer and stroke).3 The estimated direct cost of COPD in
the United States in 2004 was $20.9 billion. When the
indirect cost of COPD due to lost productivity is included
($16.3 billion), the total societal cost of COPD is an esti-
mated $37.2 billion.4 While these numbers represent
a significant burden, they are also an underestimate of the
true impact of COPD: airflow obstruction contributes to
other serious conditions, such as ischemic heart disease,
stroke, pneumonia, and lung cancer.5e8
Underdiagnosis of COPD is a serious problem in its
management.9e11 There may be as many patients with
undiagnosed COPD as those who have been diagnosed.12 In
the United States in 2000, approximately 10 million adults
responding to the National Health Interview Survey had
been diagnosed with COPD, yet 24 million adults with mild
or moderate obstructive lung disease (evidence of airflow
obstruction identified with spirometric testing) were iden-
tified in the National Health and Nutrition Examination
Survey (III).4 Other studies have shown that 7.7% of the
undiagnosed general population meet the criteria for mild
to moderate COPD or asthma.12 Population studies using
spirometric assessment of smokers have found a high
proportion of undiagnosed COPD or impaired lung function
that could progress to COPD.13
Underdiagnosis of COPD is partly due to patient
behavior. Many patients fail to recognize the early symp-
toms of COPD, attributing symptoms instead to aging or
smoking itself.14 Others restrict their activities in order to
avoid sensations of dyspnea, while underestimating the
impact of these symptoms on their daily lives.15 One survey
found that roughly three-quarters of early stage COPD
patients were either unaware of their condition or reluc-
tant to consult their physician for respiratory symptoms.16
Even patients newly diagnosed with mild to moderate
COPD can be reluctant to seek further care from
a pulmonologist.17
Late diagnosis of COPD is also partly attributable to
providers. Physicians can be reluctant to use the diagnostic
term COPD, diagnosing patients instead with asthma,
chronic bronchitis, or acute respiratory infection, without
examining the underlying disease.18e20 Delays in diagnosis
may result in quicker progression of COPD and in inefficient
or inappropriate consumption of healthcare services. By
the time a diagnosis is made, patients usually have lost half
or more of the original lung capacity.21If COPD could be identified in its early stages, inter-
ventions, such as smoking cessation, vaccinations, and
other therapies to reduce patients symptoms, could be
applied to alter the course and prognosis of the disease,
improving the patients’ quality of life.22 Moreover,
healthcare utilization and expenditures could be directed
toward appropriate treatment sooner. Therefore, the aims
of the present study were to estimate the economic burden
of undiagnosed COPD in the U.S. by comparing healthcare
utilization and costs between a cohort of newly diagnosed
COPD patients and a sample of matched controls in the 12
months prior to their initial COPD diagnoses, and to
determine trends in utilization and costs over 36 months
prior to the COPD diagnosis.
Methods and materials
Study design and data source
This was a retrospective analysis using eligibility, medical,
and pharmacy claims data from United Healthcare, a large
managed care health plan in the U.S. responsible for
coordination of payments for healthcare services. United
Healthcare provides health insurance coverage for over 30
million Americans and represents one of the largest health
insurance organizations in the U.S. with a variety of plans
with varying levels of service coverage. All plans used in the
analysis provide fully-insured coverage for physician,
hospital and prescription drug services. This database has
been used in several epidemiologic and economic stud-
ies.23e27 All data are de-identified and compliant with the
Health Insurance Portability and Accountability Act of 1996
(HIPAA).
Cohort selection
COPD and control cohorts were selected using medical
claims data from services provided between January 1,
2003 and June 30, 2004 (the identification period). All
subjects had at least 12 months of continuous enrollment in
a U.S. commercial health plan with pharmacy coverage and
were aged 40 or older in order to ensure benefit entitle-
ment and reduce misclassification bias due to inaccurate
claim submissions.
COPD cohort members were identified with: (1) an
inpatient hospital (IP) or emergency department (ED)
billing claim with a primary diagnosis indicating COPD
(International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) code 491.xx, 492.xx,
496.xx); or (2) a physician claim with a primary diagnosis of
COPD plus a second medical claim with a COPD diagnosis in
any position on a separate service date; or (3) a physician
claim with a primary diagnosis of COPD and a pharmacy
Cohorts with 3 matched pairs 
COPD: 25,113
Control: 75,339
Multivariable model analysis
Subject identified with COPD: 80,914
At least 40 years of age in 2003: 74,763
No diagnosis of COPD in 12 months prior to index date: 53,321
At least 12 months continuous enrollments: 28,968
Matched control: 81,322
Cohorts with ≥36months
continuous enrollment
COPD: 8,697
Trend analysis
Figure 1 COPD and control sample selection. *Note: cohorts
for multivariate model analysis had 12 months continuous
eligibility and three matched controls. Cohorts for trend
analysis had 36 months continuous eligibility.
1746 M. Akazawa et al.claim for fluticasone propionate/salmeterol combination,
salmeterol, ipratropium or tiotropium. Each COPD subject
was assigned an index date, the date of the earliest medical
claim with a COPD diagnosis during the identification
period. COPD subjects were excluded if they had any COPD
diagnosis in the 12 months prior to their index dates.
The control cohort was selected from the subset of the
general health plan population that had at least one
medical claim during the identification period. Each control
subject was assigned an index date based on a randomly
chosen claim. Control cohort subjects could not have any
claims with a COPD diagnosis during the identification
period or the 12 months preceding their index date. Thus,
the control cohort represented a random selection of
conditions to which pre-COPD diagnosis utilization and
costs were compared.
Control cohort subjects were matched to COPD subjects
up to a 3:1 ratio using the following factors: age range (40e
44; 45e54; 55e64; 65e74; 75e84; and 85þ), gender, region
of plan membership (south, northeast, midwest, west), and
month/year of index date. Nearly 96% of COPD subjects had
three matches from the control cohort.
Measures
Demographic measures were geographic region, gender,
and age. Comorbid conditions were identified from the
diagnoses on claims and were grouped using the Clinical
Classifications Software developed by Elixhauser and
maintained by the Agency for Healthcare Research and
Quality (AHRQ).28,29 The 20 most prevalent conditions in
the study cohorts were identified.
Healthcare utilization and costs were categorized as
inpatient hospital (IP), emergency department (ED) visits,
office visits, total medical costs and total pharmacy costs.
IP and ED, both relatively infrequent, were combined into
one utilization variable (IP/ED). Costs were defined as the
amount paid by the health plan and the patient, and do not
include costs paid by other sources. All-cause healthcare
utilization and costs were calculated for both cohorts
during the 12 months preceding, and not including, the
index date. To analyze longitudinal trends, these utiliza-
tions and costs were calculated for each of the 6 months,
7e12 months, 13e18 months, 19e24 months, 25e30
months, and 31e36 months prior to the index date for COPD
subjects with at least 36 months of continuous enrollment.
Analysis
Incremental utilization and costs related to
COPD diagnosis
Healthcare utilization and cost data for the 12 months prior
to the index date were analyzed with multivariate models.
Only COPD subjects with three control matches were
included in the analyses. The numbers of IP/ED and office
visits were modeled using negative binomial (NB) regres-
sion. Costs were modeled using Blough et al.’s formula-
tion30 of a two-part cost model to address skewness of cost
data and the large number of $0 costs: a logistic regression
was first estimated to examine the determinants, and
predict the probability, of any healthcare expendituresduring the 12-month pre-index period; costs for subjects
with positive (>$0) healthcare expenditures were then
modeled using a generalized linear model (GLM) with
a gamma distribution and log link to account for the skewed
distribution of costs.31 This two-part model avoids potential
difficulties introduced by transforming (for example,
calculating the log of the costs) and retransforming the
dependent variable.31 In the NB regression, coefficients
were presented as incidence rate ratios (IRRs). In the GLM
regression, coefficients were exponentiated to represent
the ratio of expected costs in the COPD and control cohorts.
Predicted costs were also estimated using the GLM coeffi-
cients for both cohorts.
Longitudinal trends in utilization and costs
Trends in healthcare utilization and costs over 36 months
were analyzed descriptively. Means, standard deviations,
and median IP/ED events, office visits, medical costs and
pharmacy costs were summarized for each month during
the first 6 months and for 6-month intervals 7e36 months
preceding the index date. The proportions of the COPD
cohorts with positive values in the number of events and
costs were also calculated. All tests of statistical signifi-
cance employed two-tailed tests with an alpha level of
0.05. All analyses were conducted using STATA statistical
software, version 8.2 (StataCorp LP, College Station, TX).
Results
Study subjects
Initially 80,914 subjects with COPD diagnosis were identi-
fied: of those, 28,968 COPD subjects remained after
applying the inclusion and exclusion criteria (Fig. 1). Due to
matching, 81,322 control subjects were selected, for an
average of 2.8 matches per COPD subject. Of the remaining
110,290 subjects, 100,452 subjects (including 25,113 COPD
Economic burden prior to COPD 1747subjects with three control matches and 75,339 control
subjects; 9838 subjects were removed due to incomplete
data) were included for multivariable model analysis. The
longitudinal trend analysis included 8697 COPD subjects (of
the 28,968 COPD subjects) who had at least 36 months
continuous eligibility.
Subject demographics and comorbid conditions
The distribution of age category, gender and region is
presented in Table 1. The 20 most prevalent comorbid
conditions by cohorts are shown in Table 2. After the
matching, the COPD and control cohorts were of similar age
(mean 57.8 years, median 57 years), gender (50.8% male),
and geographic mix. The COPD cohort had higher preva-
lence rates for a variety of comorbid conditions compared
with the control cohort. As expected, two of the three most
prevalent conditions in the COPD cohort were respiratory-
related (i.e., respiratory infections and other lower respi-
ratory disease). Hypertension, heart disease, and lipid
disorders were among the prevalent conditions in both
cohorts, however more prevalent in the COPD cohort (43%
vs. 15% for hypertension, 41% vs. 9% for disease of the
heart, and 37% vs. 15% for lipid disorders, respectively).
Incremental utilization and costs in 12 months
The results of negative binomial regressions to model the
numbers of IP/ED visits and office visits during the 12-month
pre-index date period are displayed in Table 3. TheCOPD cohort
used significantly more resources than the control cohort. The
point estimate for the IRR indicates that COPD patients had 1.6
times more IP/ED visits and 1.5 times more office visits
compared with non-COPD patients after adjusting for age,
gender, region, and the most common comorbid conditions.Table 1 Age, region, and gender of COPD and control cohorts
COPD cohort (nZ 28,968) Control coh
Mean (SD) Median Mean (SD)
Age 58.7 (11.0) 58 57.5 (10.2)
Age categories, n (%)
40e44 2515 (8.7) 5860
45e54 8300 (28.7) 24,897
55e64 10,992 (38.0) 32,916
65e74 4140 (14.3) 11,334
75e84 2337 (8.1) 5052
85þ 684 (2.4) 1263
Gender,a n (%)
Male 14,721 (50.8) 41,303
Female 14,244 (49.2) 40,019
Region of plan membership, n (%)
Midwest 8940 (30.9) 25,307
Northeast 3737 (12.9) 10,206
South 13,468 (46.5) 37,940
West 2823 (9.8) 7869
a There were three patients whose gender was unknown in the COPThe results of the two-part models of IP/ED costs, office
visit costs, medical costs and pharmacy costs are summa-
rized in Table 4. The logistic regressions show that COPD
diagnosis was associated with significantly greater odds of
incurring positive costs (i.e., any costs; 1.6 times for IP/ED
services, 1.9 times for office visits, 3.3 times for medical
services and 1.4 times for pharmacy services) compared
with the control cohort. The GLM results show that, among
patients with positive costs, the COPD cohort had signifi-
cantly higher IP/ED, office visits, medical and pharmacy
costs relative to the controls. COPD diagnosis was associ-
ated with 1.3e1.6 times higher costs after adjusting for
background characteristics. The average estimated costs in
the COPD and control cohorts were $1229 and $679 for IP/
ED services, $646 and $408 for office visits, $3367 and $1929
for medical services, and $1242 and $841 for pharmacy
services, respectively, during the 12-month pre-index date
period.
Longitudinal trends in utilization and costs
over 36 months
The trends in all-cause IP/ED visits and office visits utili-
zation for the COPD cohort are graphically presented in
Fig. 2. The trends of all-cause medical and pharmacy costs
are presented in Fig. 3. Mean, standard deviation (SD) and
median numbers of IP/ED visits, office visits, total medical
costs and total pharmacy costs are summarized in Table 5.
Within the COPD cohort, resource use and costs showed
a slight upward trend toward the COPD diagnosis. The
number of office visits and pharmacy costs appeared to
increase relatively steadily over time. However, dramatic
increases were observed in the IP/ED visits and medical
costs during the month immediately preceding COPD
diagnosis.ort (nZ 81,322) All subjects (nZ 110,290)
Median Mean (SD) Median
56 57.8 (10.4) 57
(7.2) 8375 (7.6)
(30.6) 33,197 (30.1)
(40.5) 43,908 (39.8)
(13.9) 15,474 (14.0)
(6.2) 7389 (6.7)
(1.6) 1947 (1.8)
(50.8) 56,024 (50.8)
(49.2) 54,263 (49.2)
(31.1) 34,247 (31.1)
(12.6) 13,943 (12.6)
(46.7) 51,408 (46.6)
(9.7) 10,692 (9.7)
D cohort.
Table 2 Distribution of comorbidities across COPD and control cohorts
Comorbid condition COPD cohort Control cohort
Rank n (%) Rank n (%)
Factors influencing healthcare 1 14,970 (51.7) 1 18,220 (22.4)
Respiratory infections 2 12,831 (44.3) 10 6532 (8.0)
Other lower respiratory disease 3 12,530 (43.3) 20 3408 (4.2)
Hypertension 4 12,337 (42.6) 2 11,958 (14.7)
Diseases of the heart 5 11,904 (41.1) 7 7431 (9.1)
Symptoms, signs, ill-defined conditions 6 11,477 (39.6) 6 8083 (9.9)
Disorders of lipid metabolism 7 10,797 (37.3) 3 11,830 (14.6)
Residual codes, unclassified 8 8705 (30.1) 8 7192 (8.8)
Other connective tissue disease 9 8516 (29.4) 11 6179 (7.6)
Non-traumatic joint disorders 10 8423 (29.1) 9 6718 (8.3)
Eye disorders 11 7966 (27.5) 5 8822 (10.9)
Spondylosis, intervertebral disc, other back problems 12 7435 (25.7) 13 5323 (6.6)
Diseases of female genital organs 13 6793 (23.5) 4 9694 (11.9)
Diseases of the urinary system 14 6388 (22.1) 15 4477 (5.5)
Other skin disorders 15 5766 (19.9) 12 5806 (7.1)
Other upper respiratory disease 16 5700 (19.7) 18 3542 (4.4)
Asthma 17 5695 (19.7)
Other nervous system disorders 18 5613 (19.4)
Upper gastrointestinal disorders 19 5417 (18.7)
Diseases of arteries, arterioles, capillaries 20 5327 (18.4)
Infections and screening for infectious disease 14 4918 (6.1)
Benign neoplasms 16 4464 (5.5)
Ear conditions 17 3615 (4.5)
Diabetes mellitus without complications 19 3487 (4.3)
Comorbid conditions were identified from diagnoses on claims and were grouped using the Clinical Classifications Software developed by
Elixhauser and maintained by the Agency for Healthcare Research and Quality (AHRQ). Blank table entries indicate conditions which
were not ranked among the top 20 most frequently occurring for the specific cohort.
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Summary of findings
The retrospective administrative claims analysis revealed that
COPD patients in the U.S. had significantly more healthcare
utilization and higher costs across all services examined in the
year prior toCOPDdiagnosis thanmatched control subjects. The
COPD patients, on average, had 1.5e1.6 timesmore IP/ED visits
and office visits, and incremental annual costs for IP/ED visits,
officevisits, andmedical andpharmacy serviceswereestimated
as $550, $238, $1438 and $401, respectively, after adjusting for
age, gender, region of the U.S. and comorbid conditions. The
trend analysis for COPD patients showed that healthcare utili-
zation and costs slightly increased over time and were most
frequently consumed in the month before COPD diagnosis.
The differences in healthcare utilization and costs
between the COPD and control cohorts may be explained byTable 3 Effect of COPD diagnosis on healthcare utilization
Outcome measures (number of events per year) R
IP/ED visits N
Office visits N
Incidence rate ratios (IRRs) were calculated by adjusting for age categ
9-CM code 493.xx), and 23 most common comorbidities (excluding a
department.baseline health conditions. The COPD patients had signifi-
cantly higher prevalence rates of respiratory and non-
respiratory comorbid conditions, such as hypertension and
heart disease, which may be attributed to a common causal
agent, tobacco smoking. However, even after adjusting for
these characteristics, the COPD diagnosis was associated
with significantly higher resource utilization and treatment
costs.
The findings from this study provide information to
assess disease progression and treatment patterns among
the COPD patients prior to diagnosis. The gradual increases
in healthcare contact might be reflected by the gradual
worsening of health conditions over time, even before the
COPD diagnosis. Sudden increases in IP/ED visits might
indicate that COPD was not diagnosed until patients expe-
rienced an acute exacerbation, or sudden worsening of
respiratory conditions. Some portion of the services and
costs might have been avoided by earlier diagnosis andegression model IRRs (robust 95% CI)
egative binomial model 1.583 (1.475e1.699)
egative binomial model 1.544 (1.508e1.581)
ories, gender, region of plan membership, asthma diagnosis (ICD-
sthma) listed in Table 2. IP: inpatient hospital, ED: emergency
Table 4 Effect of COPD diagnosis on healthcare costs
Outcome
measures
Logistic regression
(any costs) [odds ratio
(robust 95% IC)]
GLM model for patients
with costs> 0 [exp(coefficient)
(robust 95% CI)]
Predicted costs for
COPD cohort
[annual costs]
Predicted costs
for control cohort
[annual costs]
IP/ED costs 1.635 (1.545e1.730) 1.344 (1.205e1.499) $1229 $679
Office visit costs 1.861 (1.685e2.056) 1.493 (1.404e1.587) $646 $408
Medical costs 3.284 (2.866e3.764) 1.634 (1.542e1.732) $3367 $1929
Pharmacy costs 1.417 (1.343e1.496) 1.369 (1.326e1.415) $1242 $841
Odds ratios and exponentiated coefficient were calculated by adjusting for age categories, gender, region of plan membership, asthma
diagnosis (ICD-9-CM code 493.xx), and 23 most common comorbidities (excluding asthma) listed in Table 2. IP: inpatient hospital, ED:
emergency department.
Economic burden prior to COPD 1749initiation of treatment. The findings may be reflective of
the current evidence in the U.S. that COPD diagnoses often
occur in the moderate stage. However, findings differ from
a phone interview study conducted in Northern Sweden
which found that COPD patients with a diagnosis of COPD
($2207) had higher healthcare and productivity costs than
COPD patients without a diagnosis ($1128).32 Discrepancies
in the findings between this study and the OLIN study are
most likely due to healthcare utilization and care seeking
behavior since the controls in this study were also patients
and sought care for other ailments, compared to the OLIN
study which was more community based assessment.
Study limitations
In addition to the common limitations known to adminis-
trative claims analysis and observational studies such as
missing data on key confounders such as demographics,
socioeconomic status, clinical validation, disease severity,
etc.,33,34 there were study-specific limitations that must be
considered in interpreting the results. For this study, theNumber of IP/ED visits per 6 months
Number of office visits per 6 months
0.00
0.30
0.60
0.90
1.20
31-36
months
25-30
months
19-24 
months
13-18 
months
7-12
months
0.00
3.00
6.00
9.00
31-36
months
25-30
months
19-24 
months
13-18 
months
7-12
months
Figure 2 Trend in healthcare utilization oAHRQ comorbidity indicators were used to control for
baseline differences in the multivariate regression models.
However, because of their discrete nature, the indicators
did not provide information about relative illness burden or
severity of conditions.
Other types of severity measures and risk adjusters, such
as Charlson comorbidity index,35,36 and sums of utilization/
costs during aprevious period,37 often are used in claims data
analyses because they summarize a patient’s illness burden
in a single value. It was important, however, to understand
the mechanics of each measure and its inherent limitations.
For example, some risk adjusters use only claims from inpa-
tient services or were developed to predict mortality, which
may not be sufficient to detect the impact on utilization and
costs. Thus, using the AHRQ comorbidity indicators to
capture the breadth of conditions that affected this study
population was considered as an appropriate choice to meet
the study purpose. Even more so important, is the lack of
data on COPD severity as defined by GOLD stage. These data,
determined through pulmonary function test results, are not
available in administrative billing data and were thereforeNumber of IP/ED visits per month
Number of office visits per month
0.00
0.05
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Figure 3 Trend in healthcare costs over 36 months prior to COPD diagnosis.
1750 M. Akazawa et al.not available for assessment in this study. Staging of COPD at
diagnosis is very likely to be confounding the assessment of
cost, as someone who is diagnosed with more advanced
disease is much more likely to have increased costs prior to
diagnosis; however the results of this study have provided
details of trends in thediagnosis ofCOPDatapopulation level
in the U.S.
Moreover, there was a concern about simultaneity bias,
in which comorbid conditions and the outcome measures,
utilization and costs, were measured during the same time
period.38 It could be assumed that having a comorbid
condition would affect the number of visits and costs. At
the same time, a patient who had frequent contacts with
a physician might be more likely to get a diagnosis. If thisTable 5 Trend in healthcare utilization and costs over 36 mont
Months prior to
COPD diagnosis
31e36
months
25e30
months
19e24
months
13e18
months
7e
mo
IP/ED visits Mean 0.33 0.33 0.38 0.37 0.3
SD 1.05 1.09 1.29 1.20 1.3
Median 0.00 0.00 0.00 0.00 0.0
% >0 e e e e
Office visits Mean 4.57 4.96 5.23 5.33 5.2
SD 5.89 6.11 6.48 6.40 6.5
Median 3.00 3.00 3.00 3.00 3.0
% >0 e e e e
Total
medical
costs
Mean 1864 1844 2308 2456 232
SD 12,049 5911 10,844 9734 964
Median 298 361 393 423 40
% >0 e e e e
Total
pharmacy
costs
Mean 629 745 835 904 97
SD 949 1092 1199 1345 149
Median 298 377 447 494 53
% >0 e e e esimultaneity exists, the estimated effect of COPD diagnosis
could be biased. Nevertheless, it would be also true that
omitting relevant variables which were positively related to
the outcomes could cause upward bias.
The results of this study provide valuable insight
regarding the progression of healthcare resource utilization
leading up to a COPD diagnosis. The month-by-month
examination of utilization and costs in this study revealed
a pattern of increasing healthcare resource consumption
and expenditures, often with a dramatic increase in the
month prior to diagnosis. These ‘‘spikes’’ in IP/ED
encounters and medical costs may be directly attributable
to the actual diagnosis of COPD. That is, they may reflect
increasing utilization as these patients’ physicians ruled ouths prior to COPD diagnosis
12
nths
1e6
months
Month
6
Month
5
Month
4
Month
3
Month
2
Month
1
4 0.5 0.06 0.06 0.06 0.07 0.08 0.17
1 2.55 0.38 0.40 0.39 0.41 0.39 0.58
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
e e 3.6 3.9 4.1 4.5 5.1 10.7
5 5.88 0.86 0.88 0.89 0.99 0.99 1.27
9 9.4 1.47 1.49 1.50 1.62 1.59 1.73
0 1.00 0.00 0.00 0.00 0.00 0.00 1.00
e e 42.1 42.8 42.8 45.6 46.0 56.3
2 4366 451 512 519 637 690 1557
0 35,371 4643 4279 3897 5521 6274 10,757
1 111 0 0 0 10 19 82
e e 48.1 48.6 48.7 50.9 52.2 65.1
9 1074 168 169 174 183 183 197
8 2005 318 315 351 327 334 360
1 456 68 68 67 80 76 97
e e 65.3 66.1 66.0 67.5 67.4 71.4
Economic burden prior to COPD 1751other diagnoses and focused on a diagnosis of COPD, or they
may reflect increasing exacerbations of symptoms that led
to a COPD diagnosis.
The consequences of an earlier diagnosis of COPD with
appropriate treatmentmay reduce this unnecessary burden.
In the short term, once diagnosed, healthcare utilization and
costs would increase because COPD patients are given
treatments to control their symptoms. However, in the long
term, total treatment costs would be saved because costly
outcomes (i.e., inpatients/emergency department visits)
are avoided by appropriate treatments. An examination of
the utilization and costs following COPD diagnosis would
provide amore complete understanding of the progression of
care for this condition and impact of diagnosis.
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